|
V69579
|
TIE-2/VEGFR-2 kinase-IN-1 |
453590-24-4 |
TIE-2/VEGFR-2 kinase-IN-1 is used to synthesize TIE-2 or VEGFR-2 inhibitors, obtained from patent WO2003022852, Example 14. |
|
V69577
|
TIE-2/VEGFR-2 kinase-IN-2 |
501693-48-7 |
TIE-2/VEGFR-2 kinase-IN-2 is a potent dual (bifunctional) inhibitor of VEGFR2 and Tie-2 with pIC50s of 8.61 and 8.56 respectively. |
|
V69575
|
TIE-2/VEGFR-2 kinase-IN-3 |
433224-09-0 |
TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptor blocker/inhibitor (antagonist) with IC50s of 6.9 nM and 3.5 nM respectively. |
|
V69574
|
TIE-2/VEGFR-2 kinase-IN-4 |
433224-29-4 |
TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptor blocker/inhibitor (antagonist) with IC50s of 5.2 nM and 5.1 nM respectively. |
|
V69576
|
TIE-2/VEGFR-2 kinase-IN-5 |
1014407-83-0 |
TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. |
|
V69578
|
Tie2 kinase inhibitor 2 |
1020412-97-8 |
Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor (antagonist) with IC50 of 1 μM. |
|
V69580
|
Zansecimab (LY-3127804) |
2415205-37-5 |
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, an angiopoietin 2 (Ang 2) monoclonal antibody (mAb). |